Shyamakant Giri, Chief Executive Officer of Gland Pharma, expressed optimism about the company's trajectory: "With the current momentum, we anticipate robust growth in the upcoming quarters." As Gland Pharma executes this expansion plan, it aims to strengthen its position in the injectable pharmaceuticals market and capitalize on the growing demand for GLP-1 therapies
Initially studied for diabetes management and obesity, GLP-1 receptor agonists (GLP-1RAs) have garnered interest for their potential in addressing substance use disorders
How NAVA Can Help With Adrenal Issues Do you see yourself anywhere in this article
Oral semaglutide is taken daily under strict fasting conditions, while injectable semaglutide is administered once weekly
Secondly, given prescriber overlap across different patient segments, a portfolio approach enables synergies, e.g., in promotional investment
Although rare, and like will all procedures, flexible sigmoidoscopies have some risks: The instrument may tear the wall of the colon which may require surgery to repair
&srotate=0)
